Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:57 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Targeting ER Stress in Vascular Dysfunction
NCT04001647 · Colorado State University · EARLY_PHASE1 · terminated · last registry update 2025-04-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “IRB approval has been withdrawn” | – | Registry record, Colorado State University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CHRM3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-08Also stopped (withdrawn): Assistance Publique - Hôpitaux de Paris, a drug against CHRM3 (NCT02138708)
- 2026-02-27Results posted on the registry: Penn State University, Acetylcholine + Sodium Nitroprusside (NCT03953326)
- 2026-02-27Also stopped (terminated): Penn State University, Acetylcholine + Sodium Nitroprusside (NCT03953326)
- 2026-02-20Also stopped (terminated): University Hospital, Lille, Formoterol-glycopyrronium co suspension (PT003) (NCT04087590)
- 2026-01-22Results posted on the registry: University of Utah, glycopyrronium cloths + Placebo (NCT04924036)
- 2025-12-22Also stopped (terminated): Jiangsu HengRui Medicine Co., Ltd., HRG2005 inhalation + Placebo to match HRG2005 inhalation (NCT06035393)
- 2025-10-14Phase 3 first posted: Miriam Freimer, Zilucoplan® (NCT07215949)
- 2025-09-19Results posted on the registry: AstraZeneca, BGF MDI HFO 320/14.4/9.6 μg + BGF MDI HFA 320/14.4/9.6 μg (NCT05573464)
- 2025-08-22Also stopped (withdrawn): Johns Hopkins University, ibogaine with magnesium treatment + 5-MeO-DMT (NCT06810765)
- 2025-08-15Also stopped (withdrawn): AstraZeneca, Treatment A: BGF MDI HFA + Treatment B: BGF MDI HFO (NCT06340581)
- 2025-06-26Phase 3 first posted: Immunovant Sciences GmbH, IMVT-1402 + IMVT-1402 (NCT07039916)
- 2025-05-28Results posted on the registry: AstraZeneca, Treatment A (BGF MDI HFO with oral activated charcoal) + Treatment B (BGF MDI HFA with oral activated charcoal) (NCT05477108)
- 2025-04-29Results posted on the registry: AstraZeneca, Treatment A: BGF MDI HFO + Treatment B: BGF MDI HFA (NCT05569421)
- 2025-02-05Results posted on the registry: Visus Therapeutics, BRIMOCHOL™ + BRIMOCHOL™ F (NCT04774237)
- 2024-12-24Also stopped (withdrawn): Dr. August Wolff GmbH & Co. KG Arzneimittel, WO3970 + Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use (NCT04159610)
- 2024-11-15Also stopped (terminated): Chiesi Farmaceutici S.p.A., Administration via pressurized metered dose inhaler (pMDI) + Administration via pressurized metered dose inhaler (pMDI) (NCT05018598)
- 2024-10-15Phase 3 first posted: Haisco Pharmaceutical Group Co., Ltd., HL231 Solution for Inhalation + Ultibro 110μg/50 μg (NCT06643078)
- 2024-09-23Phase 3 first posted: Alexion Pharmaceuticals, Inc., Gefurulimab (NCT06607627)
- 2024-09-05Results posted on the registry: Visus Therapeutics, BRIMOCHOL™ PF + Carbachol PF (NCT05270863)
- 2024-08-06Results posted on the registry: Johns Hopkins University, [F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide) (NCT04055467)
- 2024-06-06Results posted on the registry: Botanix Pharmaceuticals, Sofpironium Bromide Gel, 15% + Vehicle (NCT03836287)
- 2024-05-30Phase 3 first posted: UCB Biopharma SRL, Zilucoplan (NCT06435312)
- 2024-05-21Results posted on the registry: Botanix Pharmaceuticals, Sofpironium Bromide, 15% + Vehicle (NCT03948646)
- 2024-05-07Results posted on the registry: Catalyst Pharmaceuticals, Inc., Amifampridine Phosphate (NCT03579966)
- 2024-05-07Also stopped (terminated): Catalyst Pharmaceuticals, Inc., Amifampridine Phosphate (NCT03579966)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision